Cirrhosis and Portal Hypertension

The natural course of cirrhosis is associated with development of portal hypertension including hyperdynamic circulation, bacterial translocation and activation of systemic inflammation cascade. The development and progression of complications will cause the shift from “compensated” to “decompensated” cirrhosis. Decompensated cirrhosis includes ascites, variceal bleeding, portal vein thrombosis, hepatic encephalopathy, hepatorenal syndrome and bacterial infections that increase the rate of  patient morbidity and mortality. This group is mainly focused in prevention, diagnosis and management of such complications, from “bench to bedside”. Clinical and translational research projects are mainly focused on the coagulopathy of liver cirrhosis with specific interest in pathogenic mechanisms of portal vein thrombosis development, on the evaluation of radiological treatment called TIPS (transjugular intrahepatic portosystemic shunt), on the beta-blockers effects in cirrhotic patients with refractory ascites as well as on the analysis of clinical impact of bacterial infections in patients with end stage liver disease awaiting liver transplantation.


  1. Senzolo M., Germani G, Cholangitas E., Burra P, Burroughs A.K. Veno occlusive disease: update on clinical management. World Journal of Gastroenterology 2007;13(29):3918-3924
  2. Senzolo M, Sartori MT, Rossetto V, Burra P, Boccagni P, Gasparini D, Miotto D, Simioni P, Tsochattzis E, Burroughs AK. Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrmbosis in cirrhosis. Liver International 2012; 32(6):919-27.
  3. Franceschet I, Zanetto A, Ferrarese A, Burra P, Senzolo M. Therapeutic approaches for portal biliopathy: A systematic review. World J Gastroenterol. 2016;22(45):9909-9920.
  4. Zanetto A, Senzolo M, Vitale A, Cillo U, Radu C, Sartorello F, Spiezia L, Campello E, Rodriguez-Castro K, Ferrarese A, Farinati F, Burra P, Simioni P. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis. 2017 Apr;49(4):440-445
  5. Russo FP, Zanetto A, Campello E, Bulato C, Shalaby S, Spiezia L, Gavasso S, Franceschet E, Radu C, Senzolo M, Burra P, Lisman T, Simioni P. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct acting antivirals. Liver Int. 2018 May 8.


Ordinary department funding.

People involved:

Patrizia Burra, Full Professor
Francesco Paolo Russo, Associate Professor

Group members:

Martina Gambato, Giacomo Germani and Marco Senzolo (Consultant Hepatologists); Alberto Zanetto, Alberto Ferrarese, Chiara Becchetti, Salvatore Sciarrone and Sarah Shalaby (Gastroenterology Fellows).